By Diagnostic World Staff
October 26, 2023 | Mayo Clinic and Oxford Nanopore Technologies teams up in a multi-year joint development collaboration to help improve patient care, including some of the hardest-to-characterize conditions and sequencing DNA; Walgreens and the Cardiovascular Research Foundation (CRF) collaborates to drive the PREVUE-VALVE study, which will help pave the way for the development of new therapies and tools for VHD detection and diagnosis; Genialis announces a new data-sharing collaboration with Cancer Research Horizons to better predict responses to KRAS inhibitors, immunotherapies, and other emerging classes of therapeutics; and more.
Mayo Clinic and Oxford Nanopore Technologies unveiled a multi-year joint development collaboration to develop new clinical tests for diseases and improve patient care. Mayo Clinic and Oxford Nanopore have identified several areas of development, spanning a wide breadth of applications from translational research in human genetics to detection of genetic predisposition to cancer. Press release.
Walgreens and the Cardiovascular Research Foundation (CRF) announced a collaboration to drive forward the PREVUE-VALVE study, a groundbreaking population-based clinical trial that aims to quantify the prevalence of valvular heart disease (VHD) among older Americans and pave the way for the development of new therapies and tools for VHD detection and diagnosis. Press release.
Genialis announced a new data-sharing collaboration with Cancer Research Horizons (CRH), the innovation arm of Cancer Research UK. Under the terms of the collaboration, CRH will make anonymized and curated datasets with 'omics and clinical metadata available to Genialis to validate Genialis ResponderID technology and machine learning-derived patient classifiers. This program will support validating Genialis-developed algorithms on diverse patient populations to better predict responses to KRAS inhibitors, immunotherapies, and other emerging classes of therapeutics. Press release.
Aspen Neuroscience announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ANPD001 for the treatment of Parkinson's disease (PD) to improve motor function. ANPD001, is a personalized (autologous) cell therapy under investigation to treat PD by replacing lost dopamine neurons. The purpose of Fast Track Designation is to get important new drugs to patients earlier. FDA grants Fast Track Designation (FTD) to facilitate development, and to expedite the review of medicines to treat serious conditions and fill an unmet medical need. Benefits of FTD include early and frequent interactions with FDA during the clinical development process, as well as eligibility for accelerated approval and priority review. Press release.
C2i Genomics and Gustave Roussy announced a new collaborative trial, 'The UMBRELLA Trial,' aimed at establishing the clinical utility of circulating tumor DNA (ctDNA) based molecular residual disease (MRD) testing in guiding immunotherapy escalation in the post-definitive care setting across early-stage solid tumors. The collaboration brings together the expertise and resources of each organization to perform a randomized multicenter clinical trial across multiple hospitals in France. Gustave Roussy will act as a central clinical partner in France throughout the research process. Press release.
Revvity announced a value-added distribution agreement with SCIEX, a global leader in life science analytical technologies. This strategic agreement is aimed at advancing mass spectrometry solutions in Revvity's newborn screening products and the anticipated solution combines Revvity’s expertise and resources with SCIEX’s innovative mass spectrometry solutions. With this agreement, Revvity hopes to further help laboratories identify newborn babies with a range of rare disorders, from lysosomal storage disorders to amino acid disorders. Press release.
Metabolon launched its new Liver Fibrosis and Kidney Function Discovery Panels. As part of the Metabolon Discover portfolio of metabolomics services, Metabolon's new Liver Fibrosis and Kidney Function Discovery Panels assess multiple metabolites across diverse biological pathways associated with liver fibrosis and kidney disease, providing a greater understanding of these conditions. These new panels also leverage new visualization tools, allowing researchers to compare results across different data sets to identify and understand the impact of statistically significant changes in metabolite abundance. Press release.
M42 has unveiled an advancement in healthcare technology with the launch of Med42, a new open-access Clinical Large Language Model (LLM). The 70 billion parameter, generative AI model is poised to transform the future of AI across the healthcare sector and create a direct impact on patient care outcomes. Med42 has the potential to revolutionize the pace of clinical decision-making, acting as an AI assistant for healthcare professionals. The capability of the model extends to developing personalized treatment plans by analyzing a patient's medical history to identify the best course of treatment. Press release.
Sengenics Corporation has launched i-Ome Discovery, a comprehensive protein microarray platform for the analysis of autoantibodies associated with disease diagnosis and therapeutic intervention. The i-Ome Discovery platform was developed to support academic and clinical biopharmaceutical research teams who are seeking to better understand the dynamic interactions and relationships between proteins, the immune system, and disease. i-Ome Discovery leverages Sengenics’ patented KREX technology, which presents full-length autoantigen proteins that are properly folded and fully functional, allowing for highly sensitive, specific, and reproducible autoantibody detection. I-Ome Discovery provides over 1,800 autoantigens that were selected for their biological relevance to several diseases, including cancer, autoimmune, and neurodegenerative disorders. Press release.
DNAnexus announced that the UK Biobank Research Analysis Platform (UKB-RAP) community has grown to more than 5,000 users around the world. The UKB-RAP was designed to allow researchers to access and analyze the exponentially increasing scale of the UK Biobank (UKB) dataset, which now contains more than 28 petabytes (PB) of biomedical data, making it the world’s largest and most comprehensive resource for researchers looking to advance the understanding of human disease. Press release.
BPGbio announced the commercial launch of the NAi (pronounced “nye”) Interrogative Biology Platform, the company’s AI-powered platform technology for broad scale development and repurposing of drugs, identification of diagnostic biomarkers, and health analytics. The platform has already delivered groundbreaking results in early-access customer research collaborations with leading government, industry, and academic partners such as the United States Department of Defense (DoD), Sanofi, and Harvard Medical School. Press release.